▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

tmfebcapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

Nov 16, 2013 by Todd Campbell

Here's Why Boston Scientific Bought C.R. Bard's Electrophysiology Business

Boston Scientific is cutting costs in a bid to return to profitability. So, why did the company spend $275 million to acquire the electrophysiology business from competitor C.R. Bard?

Nov 16, 2013 by Todd Campbell

Delivering on Promises Is Key for Isis

Cost sharing among drug developers is helping keep pipelines fresh at Isis Pharmaceuticals. But translating those pipelines into approved therapies is necessary for Isis to turn profitable.

Nov 16, 2013 by Todd Campbell

How Big Data Boosts Sales at Medidata

Drug manufacturers spend billions developing new drugs and healthcare IT company Medidata plans on saving them millions by streamlining clinical trials.

Nov 14, 2013 by Todd Campbell

Better Buy: Biogen or Amgen?

Both Biogen and Amgen are fighting competition with new drugs with blockbuster potential, but is one a better buy than the other?

Nov 13, 2013 by Todd Campbell

Better Buy: WellCare, Health Net, or Centene?

Medicaid expansion offers upside for these Medicaid insurance companies, but is one a better buy than the other?

Nov 13, 2013 by Todd Campbell

Bristol-Myers Files in Japan for New Hepatitis C Drug

Bristol's choice to focus its hepatitis C program on Japan first comes as the country opens its door to drug development. That gives Bristol a potential first-to-market edge over Gilead Sciences and Johnson & Johnson in the country.

Nov 12, 2013 by Todd Campbell

Novartis' Plans to Protect Sandostatin's Billion-Dollar Franchise

Novartis' Sandostatin, used to treat the rare disease acromegaly, loses patent protection next June. With it accounting for a billion dollars in annual sales, how does Novartis plan to keep its market share?

Nov 9, 2013 by Todd Campbell

Athenahealth Is Ready to Take on the Ambulatory Health Record Market

The Meaningful Use provision of the Affordable Care Act is driving adoption of health care IT solutions, providing an opportunity for athenahealth to expand its share against rivals GE and Quality Systems' NextGen business.

Nov 9, 2013 by Todd Campbell

ICD-10 and Meaningful Use Give Cerner a Boost

Health care reform has accelerated the adoption of integrated IT solutions across health care providers, creating a multibillion-dollar opportunity for Cerner -- if it can beat out competitors McKesson and Allscripts.

Nov 6, 2013 by Todd Campbell

Baby Boomers and Specialty Drug Pipelines Offer Omnicare Upside

Drug distributor Omnicare provides investors with stable growth as aging boomers demand more treatment and drug manufacturers focus more on higher margin specialty drugs.

Nov 4, 2013 by Todd Campbell

Better Buy: UnitedHealth Group, WellPoint, or Cigna?

The Affordable Care Act presents a new slate of opportunities and challenges for insurers. Is one a better buy than another?

Nov 3, 2013 by Todd Campbell

Can Vertex Survive Post-Incivek?

Gilead Sciences and Johnson & Johnson are about to launch new oral hepatitis C treatments that will significantly reduce Vertex sales from Incivek. The company hopes drugs treating cystic fibrosis can return it to growth.

Nov 2, 2013 by Todd Campbell

Tecfidera Succeeds in Protecting Biogen's MS Market Share From Novartis' Gilenya

The stakes are high for Biogen's new oral Tecfidera, a drug the company hopes can blunt the market share growth of competitor Novarits' oral Gilenya.

Nov 1, 2013 by Todd Campbell

Medtronic's Plan to Reduce Hospital Readmissions

The Affordable Care Act is creating a variety of challenges and opportunities for health care companies. Medtronic is embracing a provision designed to reduce re-admissions by expanding into the home monitoring market.

Oct 29, 2013 by Todd Campbell

Medicaid Parity Means Millions for Health Care Providers

A provision in the Affordable Care Act boosts Medicaid payments to physician groups, providing earnings support for Mednax through 2014.

Oct 28, 2013 by Todd Campbell

Why Gilead's Sofosbuvir Is Better Than J&J's Simeprevir

The FDA advisory panel recommended both Gilead Sciences' sofosubivir and J&J's simeprivir for approval. But there are key reasons sofosbuvir has an edge over simeprivir.

Oct 28, 2013 by Todd Campbell

Torn ACL? Rotator Cuff? It's Not Just NFL Pros Driving Sports Medicine Demand

It's not just NFL Stars Sam Bradford and Reggie Wayne Tearing ACLs. Athletes young and old are increasingly driving demand for sports medicine, an industry likely to benefit from the Affordable Care Act.

Oct 25, 2013 by Todd Campbell

Here's Why Medivation Jumped Higher This Week

Shareholders applauded phase 3 data reported by Medivation this week, anticipating the data paves the way to removing a competitive advantage held by Johnson & Johnson.

Oct 24, 2013 by Todd Campbell

Amgen Reports Strong Numbers, But Better Days May Be Coming

Amgen saw rapid growth for Xgeva and Prolia in the third quarter, but future growth may be driven by Asian partnerships, new drugs, and Amgen's acquisition of Onyx Pharmaceuticals.

Oct 24, 2013 by Todd Campbell

A Changing of the Guard in Treating Multiple Sclerosis

A slate of promising new oral MS treatments are either hitting the market or in late-stage trials. These drugs from Novartis, Sanofi, Teva, and Biogen are set to capture a large and growing share of the MS market as patients shift away from self-injection treatments.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services